Opendata, web and dolomites

NovLeuReg

Identification and characterization of novel essential regulators of acute myeloid leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovLeuReg project word cloud

Explore the words cloud of the NovLeuReg project. It provides you a very rough idea of what is the project "NovLeuReg" about.

hematopoietic    cytosines    molecular    sequencing    optimism    biology    maintenance    acquiring    exploring    transferable    biochemistry    firstly    functions    epigenetics    chromatin    null    newly    realization    regulator    mutations    normal    helin    revealed    cell    inhibition    mechanisms    dna    epigenetic    enzyme    therapies    screens    researcher    malignancy    deficient    genes    phenomenon    independent    insights    depletion    uncovered    expertise    skills    broaden    functional    hydroxylates    candidates    supervised    models    accomplishment    abnormal    scientific    world    highlight    leukemogenesis    nature    methylated    mouse    reversible    leukemia    leukemic    throughput    cells    myself    myeloid    modifying    therapy    raised    regulation    proliferation    regulators    expert    plan    kristian    pharmacological    somatic    tet2    marks    shrna    drug    frequent    acute    setd5    pathogenic    cancer    immature    interacting    governing    prof    genomics    enzymes    performing    amenability   

Project "NovLeuReg" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.bric.ku.dk/research/helin_group/
 Total cost 212˙194 €
 EC max contribution 212˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2018-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 212˙194.00

Map

 Project objective

Acute myeloid leukemia is a hematopoietic malignancy characterized by the abnormal proliferation of immature myeloid cells. The implementation of high-throughput sequencing revealed that somatic mutations in various epigenetic regulators represent a frequent pathogenic phenomenon in leukemogenesis. This raised optimism for the development of new therapies in leukemia due to the reversible nature of epigenetic marks and amenability of chromatin-modifying enzymes to pharmacological inhibition. However, realization of this potential requires further research into epigenetic mechanisms governing the maintenance of leukemic cells. The overall goal of the proposed work is to characterize novel important epigenetic regulators in leukemic cells and to assess their potential as drug targets. Firstly, I plan to identify and study epigenetic regulators essential for leukemic cells deficient in TET2, an enzyme that hydroxylates methylated cytosines in DNA. This will be achieved by performing state-of-the-art shRNA screens in mouse Tet2-null leukemia models and by exploring the functions of the uncovered candidates using a range of cell biology, biochemistry, and functional genomics approaches. The second aim is to investigate the molecular functions of SETD5, a newly-uncovered epigenetic regulator of leukemic cells. This will be achieved by identifying its target genes and interacting partners in leukemic cells and by exploring the effects of its depletion on normal and cancer cells. The accomplishment of both research aims will provide new insights into epigenetic regulation of leukemic cells and highlight novel drug targets for future therapy development. The project will be supervised by Prof Kristian Helin, a world-leading expert in the field of epigenetics and cancer. Through this work, I aim to broaden my scientific expertise by acquiring numerous technical and transferable skills and to establish myself as an independent researcher in the field of cancer epigenetics.

 Publications

year authors and title journal last update
List of publications.
2016 Aliaksandra Radzisheuskaya, Daria Shlyueva, Iris Müller, Kristian Helin
Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression
published pages: e141-e141, ISSN: 0305-1048, DOI: 10.1093/nar/gkw583
Nucleic Acids Research 44/18 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVLEUREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVLEUREG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More  

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

RegulatioNFkB (2019)

Deciphering transcriptional regulation of NF-kB target genes using integrative omics approaches

Read More